Skip to main content

Table 1 Baseline features, final diagnoses and outcome of 340 patients of the NIDIAG neurology cohort with available T. solium antigen results

From: High frequency of Taenia solium antigen positivity in patients admitted for neurological disorders in the Rural Hospital of Mosango, Democratic Republic of Congo

  Total participants evaluated (n = 340) TS antigen negative participants (n = 297) TS antigen positive participants (n = 43) P
Features at presentation n (%) n (%) n (%)  
Male sex 159 (46.8) 137 (46.1) 22 (51.2) 0.5
Female sex 181 (53.2) 160 (53.8) 21 (48.8) 0.5
Age > 20 years 270 (79.4) 231 (77.8) 39 (90.7) 0.05
Prior contact with primary care facility 159 (46.8) 141 (47.5) 18 (41.9) 0.4
Neurological symptoms > two weeks 190 (55.9) 168 (56.6) 22 (51.2) 0.5
Fever reported/documented 99 (29.1) 89 (30.0) 10 (23.3) 0.3
Severe headache 156 (45.9) 136 (45.8) 20 (46.5) 0.9
Severe headache without fever 101 (29.7) 86 (29.0) 15 (34.9) 0.4
Gait/walking disorders 97 (28.5) 86 (29.0) 11 (25.6) 0.6
Seizure 84 (24.7) 73 (24.6) 11 (25.6) 0.8
Focal sensory-motor deficit 77 (22.6) 67 (22.6) 10 (23.3) 0.9
Cognitive and/or behavior disturbance 72 (21.2) 60 (20.2) 12 (27.9) 0.2
Altered state of consciousness 69 (20.3) 61 (20.5) 8 (18.6) 0.7
Final diagnoses n (%) n (%) n (%)  
Confirmed targeted infections 84 (24.7) 76 (25.6) 8 (18.6) 0.3
Confirmed and suspected infections 119 (35.0) 107 (36.0) 12 (27.9) 0.2
Non-communicable conditions 156 (45.9) 134 (45.1) 22 (51.2) 0.4
Epilepsy 60 (17.6) 51 (17.2) 9 (20.9) 0.5
Psychiatric disorders 53 (15.6) 47 (15.8) 6 (14.0) 0.7
Myelo-radiculo-neuropathic syndromes 37 (10.9) 30 (10.1) 7 (16.3) 0.2
Cerebrovascular accident 23 (6.8) 20 (6.7) 3 (7.0) 0.9
Outcome n (%) n (%) n (%)  
Death 26 (7.6) 23 (7.7) 3 (7.0) 0.8
  1. TS denotes Taenia solium